MPL and autoimmune thrombocytopenic purpura: Rituximab is a monoclonal antibody targeting CD20 on B cells that is used to suppress antibodies that are responsible for platelet destruction in ITP.[30] Thrombopoietin receptor agonists, including eltrombopag and romiplostim, stimulate megakaryocyte production in bone marrow to enhance platelet production.[29] Splenectomy is the definitive treatment option for ITP, particularly in chronic or refractory cases.[30]